(Q33566395)

English

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group (English)

1 reference

Europe PubMed Central

28 July 2017

0 references

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Susan Halabi

2

0 references

Philip W. Kantoff

object named as

Philip Kantoff

12

0 references

13

object named as

Ethan Basch

1 reference

Europe PubMed Central

28 July 2017

18

object named as

George Wilding

1 reference

Europe PubMed Central

28 July 2017

3

object named as

Ian Tannock

1 reference

Europe PubMed Central

28 July 2017

author name string

Howard I Scher

1

1 reference

Europe PubMed Central

28 July 2017

Michael Morris

4

1 reference

Europe PubMed Central

28 July 2017

Cora N Sternberg

5

1 reference

Europe PubMed Central

28 July 2017

Michael A Carducci

6

1 reference

Europe PubMed Central

28 July 2017

Mario A Eisenberger

7

1 reference

Europe PubMed Central

28 July 2017

Celestia Higano

8

1 reference

Europe PubMed Central

28 July 2017

Glenn J Bubley

9

1 reference

Europe PubMed Central

28 July 2017

Robert Dreicer

10

1 reference

Europe PubMed Central

28 July 2017

Daniel Petrylak

11

1 reference

Europe PubMed Central

28 July 2017

William Kevin Kelly

14

1 reference

Europe PubMed Central

28 July 2017

William D Figg

15

1 reference

Europe PubMed Central

28 July 2017

Eric J Small

16

1 reference

Europe PubMed Central

28 July 2017

Tomasz M Beer

17

1 reference

Europe PubMed Central

28 July 2017

Alison Martin

19

1 reference

Europe PubMed Central

28 July 2017

Maha Hussain

20

1 reference

Europe PubMed Central

28 July 2017

Prostate Cancer Clinical Trials Working Group

21

1 reference

Europe PubMed Central

28 July 2017

language of work or name

0 references

publication date

1 March 2008

1 reference

Europe PubMed Central

28 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

28 July 2017

26

1 reference

Europe PubMed Central

28 July 2017

1148-1159

1 reference

Europe PubMed Central

28 July 2017

7

1 reference

Europe PubMed Central

28 July 2017

Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

The natural history of noncastrate metastatic prostate cancer after radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

Prostate cancer clinical trial end points: "RECIST"ing a step backwards.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

The androgen axis in recurrent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

Intermittent chemotherapy in metastatic androgen-independent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

Is the randomized clinical trial the gold standard of research?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

The control of prostate-specific antigen expression and gene regulation by pharmacological agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

21 June 2018

A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

31 October 2018

Second-line chemotherapy for prostate cancer: patient characteristics and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

31 October 2018

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

31 October 2018

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

31 October 2018

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

31 October 2018

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

31 October 2018

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010133

31 October 2018

Clinical states in prostate cancer: toward a dynamic model of disease progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/18309951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18309951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/18309951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The quantification of PSA mRNA copies in pathologically normal pelvic lymph nodes is a viable prognostic indicator

1 reference

https://pubmed.ncbi.nlm.nih.gov/18309951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations

1 reference

https://pubmed.ncbi.nlm.nih.gov/18309951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18309951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18309951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18309951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative value of bone scintigraphy and radiography in monitoring tumor response in systemically treated prostatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18309951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18309951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2007.12.4487

1 reference

Europe PubMed Central

28 July 2017

release_2wumuvpp7zbbradkmhlkudcofu

1 reference

https://api.fatcat.wiki/v0/release/2wumuvpp7zbbradkmhlkudcofu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33566395&oldid=1842341210"